The ratings on New York, N.Y.-based Bristol-Myers Squibb Co. reflect the company's diverse product portfolio, the addition of several promising new products over the past several years, and modest financial risk profile. Bristol-Myers' portfolio remains diverse, with strong positions in the oncology, cardiovascular, and virology markets. The portfolio is anchored by the anti-platelet aggregation agent, Plavix, which potentially accounts for roughly 25% of sales. Plavix's U.S. patent, which runs to November 2011, has been upheld by the courts, amidst a patent challenge from generic drug maker, Apotex. Plavix sales have rebounded nicely since supplies of Apotex's generic version of the drug have been depleted. Plavix continues to hold a dominant market share. However, Eli Lilly's rival drug, Effient, is in
